The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Hepatic neuroendocrine metastases: chemo- or bland embolization?
Susan C Pitt; Jaime Knuth; James M Keily; John C McDermott; Sharon M Weber; Hebert Chen; William S Rilling; Edward J Quebbeman; David M Agarwal; Henry A Pitt (Profiled Author: Henry Pitt)
Department of Surgery, Indiana University, 535 Barnhill Dr., RT103D, Indianapolis, IN, USA.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2008;12(11):1951-60.
INTRODUCTION: Aggressive management of hepatic neuroendocrine (NE) metastases improves symptoms and prolongs survival. Because of the rarity of these tumors, however, the best method for hepatic artery embolization has not been established. We hypothesized that in patients with hepatic NE metastases, hepatic artery chemoembolization (HACE) would result in better symptom improvement and survival compared to bland embolization (HAE). METHODS: Retrospective review identified all patients with NE hepatic metastases managed by HACE or HAE at three institutions from January 1996 through December 2007. RESULTS: We identified 100 patients managed by HACE (n = 49) or HAE (n = 51) that were similar with respect to age, gender, and primary tumor type. The percentage of patients experiencing morbidity, 30-day mortality, and symptom improvement were similar between the two groups (HACE vs. HAE: 2.4% vs. 6.6%; 0.8% vs. 1.8%; and 88% vs. 83%, respectively.) No differences in the median overall survival were observed between HACE and HAE from the time of the first embolization procedure (25.5 vs. 25.7 months, p = 0.79). Multivariate analysis revealed that resection of the primary tumor predicted survival (73.8 vs. 19.4 months, p < 0.04). CONCLUSIONS: These data suggest that morbidity, mortality, symptom improvement, and overall survival are similar in patients with hepatic neuroendocrine metastases managed by chemo- or bland hepatic artery embolization.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Peter D Peng; Omar Hyder; Mark Bloomston; Hugo Marques; Celia Corona-Villalobos; Elijah Dixon; Carlo Pulitano; Kenzo Hirose; Richard D Schulick; Eduardo Barroso; et al.HPB : the official journal of the International Hepato Pancreato Biliary Association 2012;14(8):523-31.
Susan C Pitt; Henry A Pitt; Marshall S Baker; Kathleen Christians; John G Touzios; James M Kiely; Sharon M Weber; Stuart D Wilson; Thomas J Howard; Mark S Talamonti; et al.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2009;13(9):1692-8.
David A Kooby; Vasili Egnatashvili; Swetha Srinivasan; Abbas Chamsuddin; Keith A Delman; John Kauh; Charles A Staley; Hyun S KimJournal of vascular and interventional radiology : JVIR 2010;21(2):224-30.
Appears in this Publication
Author of this Publication